Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.5 USD | -0.79% | +2.17% | +45.94% |
Financials (USD)
Sales 2024 * | 42.22M | Sales 2025 * | 114M | Capitalization | 1.85B |
---|---|---|---|---|---|
Net income 2024 * | -318M | Net income 2025 * | -361M | EV / Sales 2024 * | 42.1 x |
Net cash position 2024 * | 68.82M | Net Debt 2025 * | 36.47M | EV / Sales 2025 * | 16.5 x |
P/E ratio 2024 * |
-5.93
x | P/E ratio 2025 * |
-5.52
x | Employees | 385 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.65% |
Latest transcript on Agios Pharmaceuticals, Inc.
1 day | -0.79% | ||
1 week | +2.17% | ||
1 month | +11.15% | ||
3 months | +43.68% | ||
6 months | +54.69% | ||
Current year | +45.94% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Goff
CEO | Chief Executive Officer | 55 | 22-08-07 |
Cecilia Jones
DFI | Director of Finance/CFO | 49 | 22-09-25 |
Jacqualyn Fouse
CHM | Chairman | 62 | 17-12-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Capello
BRD | Director/Board Member | 69 | 23-05-31 |
Director/Board Member | 64 | 14-12-08 | |
May Kin Ho
BRD | Director/Board Member | 71 | 15-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.52% | 1 M€ | -4.80% | - | |
0.16% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 32.5 | -0.79% | 660,890 |
24-04-29 | 32.76 | +4.03% | 734,933 |
24-04-26 | 31.49 | -0.57% | 419,310 |
24-04-25 | 31.67 | -.--% | 721,957 |
24-04-24 | 31.67 | -0.44% | 643,302 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.94% | 1.85B | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.37% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- AGIO Stock